Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow buddies...thanks for all the charts...but BO news will wipe all your charts away!!!
NO ONE SHOULD SET STOP LOSSES FOR MMs TO TRIGGER WHILE WAITING FOR BIG NEWS!
I don't think you can see .05 this life!
I think you should read this post:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132242155
I hope many investors that are deeply underwater report these illegal activities to SEC!!!
Hope the SEC watch AMDA's trading activities closely!
Zimmer has one or is acquiring ones as well..I read a link somewhere.
No dude...it's just a robotic arm to assist the surgery process...it's not the products to implant inside the patients:
http://www.stryker.com/en-us/products/Orthopaedics/MakoRobotic-ArmAssistedSurgery/index.htm
They are in deep trouble with their knee products man:
https://www.google.com/search?q=stryker+knee+replacement+recall+triathlon&oq=strykers+knee+&aqs=chrome.5.69i57j0l5.17805j0j4&sourceid=chrome&ie=UTF-8
Plus, Zimmer's heading the robotic assisted procedure too.
Most important is the biomaterial they are using or will be used later.
Finding FAIR VALUE is the key to successful acquisition. Either the deal price favors Zimmer Biomet or Amedica will quickly triggers this type of investigation (see how fast it happened? ...instantly, moment right after the announcement of Amazon acquiring Whole Food Market):
http://www.marketwatch.com/story/whole-foods-buyout-by-amazon-investigated-by-shareholder-rights-firms-2017-06-16
Especially, Sonny's relationship with Zimmer Biomet David:
http://www.oref.org/about/governance
Make them have to be more careful on the valuation of acquisition price! Preventing lawsuits against the boards of both acquirer & target company post acquisition regarding if the board breached fiduciary responsibilities with the price of the sale of the company.
Meticulously measuring the FAIR VALUE of this speculative acquisition is extremely important for both Zimmer Biomet & Amedica. Zimmer Biomet had bad reputation with SEC lately, and the SEC is probably closely watching them:
https://www.sec.gov/news/pressrelease/2017-8.html
http://www.reuters.com/article/us-zimmer-biomet-penalty-idUSKBN14W2RV
Once must think why they settled this case in Q1, 2017? Are they preparing themselves for the next big acquistion in process? Hmm...Don't you guys see the timing of all these activities? Even the China manufacturing facility issues resolved lately...Hmm.
All this ongoing scrutiny of Amedica's 3 years fiancial reports (GAAP) is also very important & they actually found errors regarding the stocks, warrants, cash dividends, etc... on their 3rd Quarter 10-Q, 2016:
This is their 10-Q/A for 3rd Quarter, 2016 to address the found errors:
http://investors.amedica.com/all-sec-filings#document-1692-0001493152-17-004119
Acquirer's long list of homework:
https://www.forbes.com/sites/allbusiness/2014/12/19/20-key-due-diligence-activities-in-a-merger-and-acquisition-transaction/#2ca2ea804bfc
Now look at...11. General Corporate Matters. Counsel for the buyer will invariably undertake a careful review of the organizational documents and general corporate records (including capitalization) of the target company, including:
Lists of all security holders (common, preferred, options, warrants)
Stock option agreements and plans, including both standard documents and any deviations therefrom
Warrant agreements
Stock sale agreements
Stock appreciation rights plans and related grants
Agreements granting restricted stock units
Stockholder and voting agreements
Stock-related preemptive rights, registration rights, redemption rights, or co-sale rights
Agreements restricting the payment of cash dividends
Evidence that securities were properly issued in compliance with applicable securities laws, including applicable federal and state blue sky laws
More dots are being connected about buying Amedica in being in processed.
Every industry, there are analysts & experts that keep track of every move of the big boys in the industry. They analyze their moves & sometimes foresee things we don't, it's their job. Like this article on amazon:
https://www.thestreet.com/slideshow/14183083/1/6-surprising-ways-amazon-will-use-its-new-13-7-billion-prize-whole-foods-to-make-even-more-money.html
The contents of these Zimmer articles from those experts also align with our prediction that something big is coming to theater near us...hahaha.
FYI...Zimmer Bimomet stock (ZBH) is climbing lately.
Blackrock invested almost $2 billions in ZBH...Is there something those guys know, but we don't.
I won't doubt a bit!
Zimmer's manufacturing facility issues resolved in China:
"We believe this development should not just help the company regain goodwill in the market but the successful run of the Chinese manufacturing facility should also help it boost the profit margins by curtailing operating expenses."
"Zimmer Biomet expects to establish a critical mass in both spine and dental departments to position it well to compete effectively and gain a plum share in these significant markets."
Additionally, the latest development should also add an impetus to the company's emerging market growth trajectory. In the recent past, Zimmer has been working hard to strengthen its foothold in the emerging markets to acquire long-term growth opportunities. (Think China Weigao deals with Amedica)
"Opportunity from emerging markets is expected to grow to $10 billion by 2018 for the Reconstructive and Trauma areas."
http://www.nasdaq.com/article/fda-passes-zimmer-biomets-zbh-zhejiang-facility-issue-cm803147
Amedica's brand new patents of 2nd. Gen worldwide patents is perfect for this (The Osteoconductivity increased 190% over current silicon nitride composition) https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017027426:
Reconstructive and Trauma areas. <<<< maxillofacial skeletal reconstruction.
https://www.ncbi.nlm.nih.gov/pubmed/12418561 and also
Bone defects repairiing & Bone Regeneration.
https://www.google.com/search?q=Reconstructive+and+Trauma&oq=Reconstructive+and+Trauma&aqs=chrome..69i57&sourceid=chrome&ie=UTF-8#q=reconstructive+and+trauma+bone+growth
Historical Price & Volume:
https://finance.yahoo.com/quote/AMDA/history?p=AMDA <<<<< volume from yesterday shows "344,100"
http://www.nasdaq.com/symbol/amda/historical
====================================================
Now look closely at these links for total volume:
http://shortvolume.com/ <<<< change the ticker to "amda"
http://nakedshortreport.com/?index=AMDA
https://www.quandl.com/data/FINRA/FNSQ_AMDA-FINRA-NASDAQ-TRF-Short-Interest-AMDA
Even the official FIRNA page shows less volume too:
http://regsho.finra.org/FNSQshvol20170615.txt <<<< search "amda" yields:
Date|Symbol|ShortVolume|ShortExemptVolume|TotalVolume|Market
20170615|AMDA|20899|427|74356|Q
=================================================
Can you guys see the total volume of the above 4 links only shows the yesterday's volume of "74356", but the actual volume of yesterday was 344,100....I have been tracking this for weeks. The reported total volume of so many days were wrong. I bet the shorted volume were wrong as well. I have a feeling these guys are holding a bunch of naked shares!
Why??? I am thinking of this:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=18742
Please pay close attention at Level 2 trading data...
Which is so illegal!
Here is the page to report them:
https://www.sec.gov/oiea/Complaint.html
If you are a real long & your positions are being burned by these thieves. Should report this to SEC! This is the only way to fight back!
Amazon to Acquire Whole Foods Market:
"Whole Foods Market will continue to operate stores under the Whole Foods Market brand and source from trusted vendors and partners around the world. John Mackey will remain as CEO of Whole Foods Market and Whole Foods Market’s headquarters will stay in Austin, Texas."
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20170616:nBw7m48Qva
This is a example of strategic fit between buyer & target company as Amazon always want to expand their grocery business.
=====================================================
IMO...The above example similarly depicts the current scenario between Zimmer Biomet & Amedica...strategic fit between both. Zimmer Biomet has the resources of sale channels & connections, but lack the tech. Amedica has the tech, but lack the resources & connections to maximize the usage of their unique, superb, biomaterial Si3N4. It will be a win-win scenario for both as soon as the speculative acquisition is finalized! IMO, post acquisition, Amedica will be operating under the same name, but as subsidiary of Zimmer Biomet due to Amedica's super clean image in the Orthopaedic industry.
Two years of rumor...hopefully soon, it will turn into a "TRUE-mor".
NT 10-Q filed on 5.8.2015
https://www.sec.gov/Archives/edgar/data/3116/000117184315002690/f12b25_050815.htm
=======================================================================
On 5.19.2015 (11 days after the NT 10-Q), they filed 8k to update investors about the waiver to their lender for non timely to file Financial Statements:
https://www.sec.gov/Archives/edgar/data/3116/000117184315002991/gff8k_051915.htm
Weird right? This is the 3rd examples I found...AMDA never filed a similar 8K to update investors about "waiver" they ask from Hercules even the 10K, 10Q is way overdue.
======================================================================
The similar 8K like the ones AMDA filed on 5.26.2017 to update investors about the delisting warning letter from Nasdaq they received on 5.23.2017:
"On May 12, 2015, Akorn Inc. (the "Company") received a written Staff Determination Notice ("Notice") from the NASDAQ Stock Market ("NASDAQ"), stating that the Company is not in compliance with NASDAQ Marketplace Listing Rule 5250(c)(1) for continued listing because the Company has not timely filed the Quarterly Report on Form 10-Q for the fiscal quarter for the period ended March 31, 2015 (the "filing"). On May 14, 2015 the Company also issued a press release disclosing the receipt of the notice and a copy of the press release has been furnished as Exhibit 99.1 to this report.
The Notice indicates that the Company has until July 13, 2015 to submit a plan of compliance to NASDAQ addressing any issues it believes would support its request for an extension of up to 180 calendar days from the due date of the filing. The Company intends to submit a plan of compliance to NASDAQ within the 60-day window and the Company will take all necessary steps to achieve compliance with all NASDAQ listing requirements. During this process, the Company expects that its common stock will continue to be listed and traded on the NASDAQ Stock Market.
On May 12, 2015, Akorn Inc. (the "Company") received a written Staff Determination Notice ("Notice") from the NASDAQ Stock Market ("NASDAQ"), stating that the Company is not in compliance with NASDAQ Marketplace Listing Rule 5250(c)(1) for continued listing because the Company has not timely filed the Quarterly Report on Form 10-Q for the fiscal quarter for the period ended March 31, 2015 (the "filing"). On May 14, 2015 the Company also issued a press release disclosing the receipt of the notice and a copy of the press release has been furnished as Exhibit 99.1 to this report.
The Notice indicates that the Company has until July 13, 2015 to submit a plan of compliance to NASDAQ addressing any issues it believes would support its request for an extension of up to 180 calendar days from the due date of the filing. The Company intends to submit a plan of compliance to NASDAQ within the 60-day window and the Company will take all necessary steps to achieve compliance with all NASDAQ listing requirements. During this process, the Company expects that its common stock will continue to be listed and traded on the NASDAQ Stock Market."
https://www.sec.gov/Archives/edgar/data/3116/000117184315002921/document.htm
================================================================
https://www.sec.gov/Archives/edgar/data/3116/000117184315002690/f12b25_050815.htm
"Akorn Announces Nasdaq's Acceptance of Its Plan to Regain Compliance
LAKE FOREST, Ill., July 15, 2015 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), today announced that the Nasdaq Stock Market has accepted the company's plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) which will permit the continued listing of Akorn's stock on the Nasdaq Global Select Market.
As previously reported on May 18, 2015, Akorn received a letter from Nasdaq stating that the company was not in compliance with Nasdaq listing rules because the company had not filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2015 with the Securities and Exchange Commission. In the letter, Nasdaq requested that Akorn submit a plan to regain compliance with Nasdaq listing rules within 60 days.
On July 10, 2015, Akorn submitted to Nasdaq a plan to regain compliance with Nasdaq listing rules. After reviewing Akorn's plan to regain compliance, Nasdaq granted an exception to enable the company to regain compliance with the listing rules. Under the terms of the exception, Akorn must file its Form 10-Q for the quarterly period ended March 31, 2015 and all other periodic reports required by listing rules on or before November 9, 2015. In the event that Akorn does not satisfy the terms set forth in the extension, Nasdaq will provide written notification that Akorn's securities will be subject to delisting proceedings. At that time, Akorn may appeal Nasdaq's determination for a panel review."
https://www.sec.gov/Archives/edgar/data/3116/000117184315003836/newsrelease.htm
DON'T BE ALARM THAT WE DON'T SEE ANY 8K on Jun 19, 2017...it's a non issue on the delisting...WE MIGHT SEE A 8K JUST SAY PLAN ACCEPTED (MAYBE DAYS LATER AFTER JUN 19, 2017).
DON'T LISTEN TO THE MISINFO. BS ABOUT DELISTING FROM THE BEARS! All this time, the bears will try to spin BS, so they can knock the price down...to rob.
Sometimes it's not your network...it's ihub...happened to me twices this week...
China CFDA approval flow chart & info:
https://www.emergogroup.com/resources/china-process-chart
http://www.cirs-reach.com/China_Chemical_Regulation/Medical_Device_and_IVD_Registration_in_China.html
http://www.cirs-reach.com/China_Chemical_Regulation/Catalogue_of_Medical_Devices_Standard_CIRS2015.pdf
https://www.sec.gov/Archives/edgar/data/1269026/000149315217006356/form8-k.htm
https://www.sec.gov/Archives/edgar/data/1269026/000149315217006356/ex99-1.htm
Both, the recent prelim. 8K & exhibit mentioned NOTHING about China!
Weird as hell...what are they cooking in China?
I am drooling over this 220K+ units pending CFDA:
http://imgur.com/a/nl72D
http://www.amedica.com/news-media/press-releases/detail/74/amedica-signs-exclusive-chinese-silicon-nitride
Tech. transfer & agent must be local Chinese Company hence they have to work closely with Giant Weigao.
Featured Company News - Zimmer Biomet's China Manufacturing Unit Gets US FDA Nod After Addressing Violations Indicated in Warning Letter
"Due to the FDA's warning letter and till such time that the violations were not corrected, the requests for Certificates to Foreign Governments related to products manufactured at Zhejiang facility could not get premarket approval applications for the devices as they did not meet the quality system regulation (QSR) of FDA."
https://finance.yahoo.com/news/featured-company-news-zimmer-biomets-121500439.html
Wonder what type of devices (knee, hip, SPINE, etc) ??? Are they preparing to manufacture there?
looks like no penny for you to flip my friend...the mms keep the spread real tight! lmao.
Due Diligence before acquiring another company (esp. public company) is extremely important!
https://www.forbes.com/sites/allbusiness/2014/12/19/20-key-due-diligence-activities-in-a-merger-and-acquisition-transaction/#4668fe6c4bfc
1. Financial Matters.
* What do the company’s annual, quarterly, and (if available)
monthly financial statements for the last three years
reveal about its financial performance and condition?
*hint hint: Up to year end of 2016, they have solid, 3 FULL years of financial filings! 2014, 2015, 2016!
11. General Corporate Matters.
* Warrant agreements
*hint hint: http://investors.amedica.com/quarterly-reports/content/0001493152-17-004119/0001493152-17-004119.pdf (ALL ABOUT WARRANT AGREEMENTS)
"Acquirers also conduct due diligence because of litigation risk concerns."
https://business.illinois.edu/accountancy/wp-content/uploads/sites/12/2014/08/Wangerin.pdf
https://www.cornerstone.com/Shareholder-Litigation-Involving-Acquisitions-2014-Review
Preventing possible lawsuit arise post acquisition!
Measuring the Fair Value of the Target company is extremely important!
Do you guys see it? They have been going thru. the due diligence lists!
LOL...last year your friend...This year your wife? next year your GF? SMH.
What I love to see years later is peek's breakfast, lunch, dinner & supper will be all taken by valeo + CSC using 2nd gen si3n4!
As a patient's perspective...who the hell want to have 2 operations on their body versus only 1 cut using CSC procedure!
Infection is a big damn issue on peek.
W/O zimmer's taken over si3n4, then it's a diff. story...amda's resource is hard to compete with the big players out there.
https://topclassactions.com/lawsuit-settlements/lawsuit-news/684748-zimmer-recalls-persona-following-reports-of-knee-implant-complications/
Their topline knee replacement back by their "dream" trabecular metal tech...
https://www.nationalinjuryhelp.com/faqs-zimmer-persona-knee-implants/
shake my head...
Si3N4 will be their savior!
No...i don't want to work for anyone...next mission is to be in 2 next BO candidates in 2018...& 2 more in 2019 in my DDs pipelines as soon as this BO on AMDA done...hopefully soon.
I was in CPXX BO too..it was a hell fights with bears on ST...I was banned on CPXX board too like i was banned on AMDA board on ST...hahaha...
INNL BO was the easiest $$$ i ever made.
on Level 2...the bids side stay strong w/o jumping around...the manipulators on the ask side...the ask dancing around...100 shares probing...lmao...so easily spot them.
Phase 3: Preparing for the transaction
Parties make sure their teams are briefed, ready and on the same page, and sign a letter of intent before they begin the due diligence process. It is important for parties to ensure that their legal documents (e.g., option plans, board of director notes, NDAs, partnership agreements, benefits plans) are organized and in good shape. Also crucial is for parties to ensure that they have completed the proper government filings, that they have adequate product and marketing documentation, and that their financial records are sound and have been audited by a legitimate third party. HR professionals are likely to be heavily involved in the collection and organization of such records.
The parties sign a letter of intent if they tentatively can agree on the priority issues involved in the transaction. A letter of intent is a document that seeks to provide some initial points of understanding and that binds the parties to keep the information discussed confidential. This document is signed prior to the start of the due diligence process and prior to formal board of directors' approval of the deal.
During the due diligence process, it is critical to read documents carefully to eliminate any surprises that could jeopardize the deal. Parties should decide up front how much information they will share during due diligence; they should expect to have to share a significant amount of detail. Parties must have the required documentation organized and prepare multiple copies so they will not be slowed down by copy requests. In addition, parties should be aware that due diligence almost always takes longer than expected."
Employee selection and downsizing >>>(CFO gone & Controller gone)
Early placement of management is a critical factor in beginning to stabilize the new organization. Any delays in placing key managers complicate the transition by increasing uncertainty, diverting attention and fostering internal competition. A major challenge for the acquiring company is in deciding who to retain, who to redeploy and who to terminate, as well as effectively managing those processes. Relocating key personnel or even entire departments may be necessary. See Employment Downsizing and Its Alternatives.
Ideally, the HR and management teams will have been able to assess the skills, capabilities, potential and motivations of key employees involved in the merger or acquisition. Typical methods include interviewing and testing techniques and the use of outside consultants. Once these tasks are completed, the HR team should take immediate steps to "re-recruit" and place these employees into key positions of the new entity. See Should employees complete new-hire paperwork after a merger or acquisition? and How do I handle forms I-9 during a merger or acquisition?
Most M&A deals count on both the organizational and financial efficiencies that will result from a reduction in the number of employees needed to run the new organization. This outcome means that HR will spend a large amount of time assessing employee knowledge, skills and abilities (KSAs) to decide who will stay and who will go. The strategy may include terminations, early retirements and a longer-term plan to simply not fill certain positions as they are vacated. The ways in which these decisions are made will—in the long run—be as important as the actual decisions themselves. Moreover, the manner in which talent management decisions are made will communicate a great deal about what the organization values.
https://www.shrm.org/resourcesandtools/tools-and-samples/toolkits/pages/mergersandacquisitions.aspx
Most importantly Amedica's image in Ortho sector is super clean!
Billions of $ in lawsuits liability (J&J, Strykers, Zimmer's), Metal on Metal hips Replacement lawsuits:
https://www.google.com/search?q=hip+implants+lawsuit&oq=hip+implants+la&aqs=chrome.2.69i57j69i60j0l4.11143j0j7&sourceid=chrome&ie=UTF-8
Zimmer's Trabecular Recalls & lawsuits:
https://www.google.com/search?q=trabecular+metal+lawsuit&oq=trabecular+metal+lawsuit&aqs=chrome..69i57.10380j0j7&sourceid=chrome&ie=UTF-8
even their old dorum cup lawsuits:
https://www.google.com/search?q=zimmer+cup+lawsuits&oq=zimmer+cup+lawsuits&aqs=chrome..69i57.9935j0j7&sourceid=chrome&ie=UTF-8#q=zimmer+dorum+cup+lawsuits
Zimmer invested in PEEK biomaterial too, turned out it was a flop too:
https://www.aboutlawsuits.com/zimmer-peek-ardis-inserter-recall-38959/
Patient: ChristopherOctober 31, 2015 at 7:02 pm Reply
Received fusion (L5-S1) Oct 27, 2009. Had a break Oct 29, 2009. They PEEK cage was ‘repaired’ Nov 2, 2009.
I have operative report and film.
Not sure what broke or ‘anchor fastener’ broke or came loose 10/29/09.
They have a legit reason to reject your article...All the REAL investors in this amda should help themselves to help to spread the DDs to other places.
I wrote a message to you on ddland.
You are welcome! In order for little the "joe", retail investors to balance the playing field with manipulators is to work together to combine DDs info. All the manipulators come to the battle field with big plans & tactics to steal $$$. Look at the 1 share @ .307 as of now in pre-market...lmao...nice try for them.
only drinks & dinner? no strip dancing? lol...hopefully news come soon man.
Japan is very important:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132071664
Si3N4 non medical grade usage:
http://www.cerobear.com/index.php?id=208
So magical...too many type of usage for Si3N4
LOL boss...like always...when you ask someone to read something...please provide a link too...
From the article:
"As patient outcomes figure more prominently in the bundled payment environment, healthcare institutions are under increased pressure to minimize inefficiencies along the entire episode of care while delivering superior quality of care and a positive patient experience," said Dr. Todd Dietrick, orthopaedic surgeon at Huntington Memorial Hospital in Pasadena, California.
Valeo + CSC is the example of that!
Amedica's Si3N4 tech. can make it happens but lack of resources (sale channels & connections).
Zimmer Biomet has the vast resources to make it happens but lack the tech.!
Combine Zimmer Biomet & Amedica = Cost Effective for healthcare institutions & less payout from insurance companies + less painful, happier patients.
Surgeons win.
Hospitals win.
Insurance Companies win.
Zimmer Biomet wins.
Amedica wins.
Shareholders win.
All I know they need si3n4 badly for their fight with Strykers, Medtronics, JnJ, & even Ceramtec, etc...many revenue streams can pull in if si3n4 is their possession.
Boston, can you try to compile a list of evidences/visions why Zimmer desperately needs AMDA's Si3N4 (in details please) for their growth & in many market penetrations (Spine, Hip, Knee, Dental, etc). I know you have a tons of DDs info in this with charts & numbers. You can try to compile a very details post on this subject.
Then all we need is to sticky this 2 posts with all the DDs...Then direct all real investors to read them.
shares accumulation can work both ways...up (happy flippers sell for pennies) & down (sell sell sell...ship is sinking)...
Alright Folks, I tried my very best to compile this list of DDs from Boston, myself & others. Some of the statements we made are just opinions based on FACTs we found. Boston, can you try to compile a list of evidences/visions why Zimmer desperately needs AMDA's Si3N4 (in details please) for their growth & in many market penetrations (Spine, Hip, Knee, Dental, etc). Can someone make this a sticky post? It would be nice if all other forums or message boards' long investors can be directed to read this post for their own DDs. On other message boards, many bears are just bash AMDA with their own, same set of opinions w/o any real facts or links to back their comments!
The Connections:
Amedica & Zimmer connection starts at the very top: Sonny Bal & David Dvorak both trustees for OREF http://www.oref.org/about/governance
#1 2012 - Who the "F" was this little Amedica (The "hate" started there!?) http://www.cafepharma.com/boards/threads/three-rivers-spine.465587/ (Stryker Board) & http://www.cafepharma.com/boards/threads/wtf-amedica.493073/ (Medtronic Board) (This is the website for Ortho Experts in the field to chit chat.)
#2 2012 - The connection to Zimmer starts right here 2012 Sonny was consultant for several companies including Amedica & Zimmer: B.S.B. is a consultant for Zimmer, Inc, Medtronic, Amedica Corporation, and ConforMIS. He is also on the corporate boards for Amedica, OrthoMind, and Bonesmart.org, and is business founder and partner in the law firm BalBrenner LLC. No conflicts of interest exist in this manuscript, and authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article. http://www.semarthroplasty.com/article/S1045-4527(12)00071-5/fulltext
#3 2013 - Amedica Signs Agreement with Kyocera for Commercial Manufacture of Silicon Nitride Medical Devices http://www.prnewswire.com/news-releases/amedica-signs-agreement-with-kyocera-for-commercial-manufacture-of-silicon-nitride-medical-devices-233494661.html
#4 2013- Amedica's trials started in the Netherlands under the oversight of Dr. Mark P. Arts & Dr Jasper Wolfs Cascade trial began in Sept 2013 and SNAP trial in Jan 2014. This isn’t normally an interesting fact, except that both of these surgeons receive grants from Zimmer & work as consultants for Zimmer. The authors MA (Mark Arts) and JW (Jasper Wolfs) receive research grants from Zimmer-Biomet, EIT and Intrinsics. MA and JW are consultants for Zimmer-Biomet and Silony and they receive royalties from EIT. https://link.springer.com/article/10.1007%2Fs00586-017-5079-6
#5 2014 - Sonny was no longer consultants for any other companies other than Amedica & Zimmer before taking over as CEO at Amedica
B. Sonny Bal, MD (2 – Journal of Arthroplasty; Knee; 4 – DePuy, A Johnson & Johnson Company – Anterior Total Hip Symposium, 11/2/07 at AAHKS Meeting; 5A – Zimmer; AMEDICA; 7 – Zimmer; 8- AMEDICA) https://www.aaos.org/ccc/contrib_conflicts.html
#6 2014 - Kyocera contemplates Vancouver expansion. A preliminary planning application filed last week with the city of Vancouver describes 10,000 square feet of additional manufacturing space and 1,500 square feet of associated office space. The company currently has 40,000 square feet of space at its site on Northeast Fourth Plain Boulevard http://www.oregonlive.com/silicon-forest/index.ssf/2014/06/kyocera_contemplates_vancouver.html
#7 2015, July 21 – Kyocera increases expansion of newbuilding from 10,000 to 18,000 sq ft. Plans filed with the city of Vancouver call for Kyocera to expand its 40,000-square-foot factory by more than 18,000 square feet with a two-story addition. http://www.oregonlive.com/silicon-forest/index.ssf/2015/07/kyocera_plans_vancouver_expans.html
#8 2015, July 22 - Word on the street is a merger/buyout with Amedica....any info or thoughts? (posted on a Zimmer board) http://www.cafepharma.com/boards/threads/amedica.583298/
#9 2015, July 23 - Amedica Corporation Signs Additional OEM Letter of Intent Supply Agreement Amedica Corporation (Nasdaq:AMDA), a biomaterial company that has developed silicon nitride ceramics as a material platform to manufacture and commercialize orthopedic implants, is pleased to announce that it has signed an original equipment manufacturer (OEM) letter of intent supply agreement with a leading orthopedic device design and manufacturing company. http://www.amedica.com/news-media/press-releases/detail/45/amedica-corporation-signs-additional-oem-letter-of-intent
#10 2015, Sept 9th- Amedica Corporation Adds Giuseppe Pezzotti, PhD to Its Scientific Advisory Board (i'm speculating Giuseppe is associated with Zimmer based on timing, no clear evidence found yet) Amedica Corporation (Nasdaq:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, today announced the appointment of internationally renowned scientist Giuseppe Pezzotti, Ph.D. to its Scientific Advisory Board. Dr. Pezzotti will advise the Company on the scientific properties and clinical applications of silicon nitride, and assist Amedica in further developing its technology. http://www.amedica.com/news-media/press-releases/detail/53/amedica-corporation-adds-giuseppe-pezzotti-phd-to-its http://aaos2017.conferencespot.org/aaos63877-1.3443042/t003-1.3448845/f003-1.3448846/a087-1.3449098/p402-1.3449117 http://www.medicalnewstoday.com/articles/308784.php (Boston, he is an expert on ceramic @ Kyoto University - Did Sonny get his PHD there?)
#11 Fall 2015 - Amedica adds Sintex on as distributor in Brazil; Biomet had a foot print of an elephant in Brazil before they merged with Zimmer - Post Merger - Zimmer Biomet (ticker ZBH) http://www.biomet.com/regions/southAmerica/brazil.cfm?passedCategory=orthopedics ...http://www.sintexmedical.com.br/home
#12 2015 on - Paul Saiz, MD. Since 2005, Dr. Saiz has worked as a Consultant for Zimmer Spine. He consulted on the Zimmer Spine TM Ardis project, and he continues to lend his expertise to the company’s Trabecular metal projects. He has also consulted for Amedica Corporation, which included training Brazilian surgeons on the Valeo pedicle screw system. http://paulsaizmd.weebly.com/ & http://files.shareholder.com/downloads/ZMH/0x0x15939/5a3a0143-4c55-479c-b811-0ab84554fc36/123310.pdf (Zimmer acquired Trabecular Metal Technology from Implex Corp. for about $200 Mils - Cash + Stock)
#13 2015-2016 - Comparative Testing of Ceramic Femoral Heads for Total Hip Arthroplasty (testing begins at same location as Biomet knee testing - indirect connection) https://www.unmc.edu/orthosurgery/research/grants.html
#14 2015-2016 Product Pipeline: Hip & Knee Replacement (pg 33) (Hip testing being done at Kyoto University which has also received grants from Kyocera & Zimmer - indirect connection) https://www.sec.gov/Archives/edgar/data/1269026/000149315216010774/fwp.htm
#15 2016 - The effects of kinematically aligned total knee arthroplasty on stress at the medial tibia Kyoto University has received grants from Zimmer Biomet in relation to this article. Funding has been received by Kyoto University from Kyocera, Smith & Nephew, Mitsubishi Tanabe Pharma Corp, Chugai Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd. and Eisai Co. Ltd, Fizer Japan Inc., Astellas Pharma Inc., AbbVie GK, AYUMI Pharmaceutical Corp., Taisho Toyama Pharmaceutical Co. Ltd., and Eisai Co. Ltd., none of which is related to this article https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301901/
#16 April 2016 - KYOCERA Breaks Ground to Expand Industrial Ceramic Manufacturing Operations in Washington State
Kyocera breaks ground of new manufacturing building 1 week after Amedica announces deal with Weigao. https://americas.kyocera.com/press-releases/press-releases_20160425.htm
#17 Nov 2016 – Amedica Announces New Sales Leadership (Dana Lyons & Ryan Long were both Zimmer VPs) http://www.amedica.com/news-media/press-releases/detail/89/amedica-announces-new-sales-leadership-and-provides & https://www.linkedin.com/in/ryanjlong/ &
https://www.linkedin.com/in/dana-lyons-a23b9550/ This 2 guys were making $ millions @ Zimmer ($25 Bil Market Cap) & switched to Amedica (a nano cap with $10 Mil Market Cap & Bashers say Amedica about to BK...LMAO..SMH)...Sounds very funny & illogical!!! Looks like they were assigned by Zimmer to go over to Amedica (Special Assignments...IMO) to prepare for the transitioning before acquisition take place. Also, in this Amedica VP search on Linked, #2 circle (Orlando Florida Area) & #5 circle (Greater New York City Area)...Could they be someone from Zimmer like Lyons & Long? http://imgur.com/a/m69QV
#18 Dec 2016 - The Effect of Cervical Interbody Cage Morphology, Material Composition, and Substrate Density on Cage Subsidence
Dr. Suh or an immediate family member has received royalties from Zimmer Biomet, is a member of a speakers’ bureau or has made paid presentations on behalf of Eli Lilly, and serves as a paid consultant to or is an employee of Amedica and Zimmer Biomet. http://journals.lww.com/jaaos/Fulltext/2017/02000/The_Effect_of_Cervical_Interbody_Cage_Morphology,.10.aspx
#19 Feb 2017 – Amedica Announces Results of Independent Femoral Head Wear Testing. This independent wear study was conducted in accordance with international standards at the Medical Technology Laboratory of the Rizzoli Orthopaedic Institute (Bologna, Italy) by Professor Aldo Toni MD under the supervision of Dr. Saverio Affatato PhD (Rizzoli Institute) with consultation and support from Professor Giuseppe Pezzotti PhD (Ceramic Physics Laboratory, Kyoto Institute of Technology, Sakyo-ku, Kyoto Japan). Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research. http://www.amedica.com/news-media/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear. Here is the details of the test: www.mdpi.com/2075-4442/4/4/35/pdf
#20 April 2017 - KYOCERA Expands Industrial Ceramic Manufacturing Operations in Washington State (new building increased 5,000 sq ft over 2016 estimate of 18,000. Head count now up to 50) The newly constructed building on the Kyocera site at 5713 N.E. Fourth Plain Boulevard expands the company’s local 40,000-square-foot manufacturing presence by more than 50 percent, to 63,000 square feet — and could create up to 50 new employment positions over the next few years. The facility currently employs approximately 140 staff members on three shifts. http://www.businesswire.com/news/home/20170420006584/en/KYOCERA-Expands-Industrial-Ceramic-Manufacturing-Operations-Washington
#21 June 2017 - Zimmer Biomet Rides on Spine Business, Knee Challenges Stay. This is in line with the strategy to grow through inorganic means by focusing on mega acquisitions. Management is also striving to develop spine portfolio in order to cash in on the opportunities....Zimmer Biomet has been of late working to strengthen its foothold in the emerging markets that provide long-term opportunities. The company's strategic investments in these regions over several quarters with a view to enhance operational and sales performance are yielding results. http://www.nasdaq.com/article/zimmer-biomet-rides-on-spine-business-knee-challenges-stay-cm800569
The most recent piece of AMDA's connection with Zimmer posted by Boston:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132126254
================================================================================================================================================
The BO Thesis:
Puzzle piece #1 No CFO since last year 3Q 2016 - Sonny is CEO & PFO http://www.amedica.com/about/management-team
Puzzle piece #2 No Controller as well, since Apr 2017 - https://www.linkedin.com/in/aaron-stout-684bb84/
* All accounting related material is being handled by BDO - http://investors.amedica.com/all-sec-filings/content/0001493152-16-011712/form8-k.htm --- https://www.bdo.com/services/consulting/corporate-finance-ma-advisory/overview
Puzzle piece #3 No 2016 10K & 2017 1Q & even NO proxy statement too
Puzzle piece #4 Lawsuit settled: "Effective November 9, 2016, we entered into a settlement and release agreement (the “Settlement Agreement”), with each of the selling stockholders named in this prospectus in full settlement of a lawsuit filed against us on April 1, 2016 by Hampshire MedTech Partners II, GP (“Hampshire GP”), on behalf of itself and the other selling stockholders, in the Travis County, Texas 200th Judicial District Court relating to a Warrant to Purchase Shares of Common Stock issued by us to Hampshire MedTech Partners II, LP. In connection with the Settlement Agreement we issued a total of 962,380 shares of our common stock to the selling stockholders. Pursuant to the Settlement Agreement, we agreed to file the registration statement of which this prospectus is a part with the Securities and Exchange Commission (the “SEC), to register the sale or other disposition of the shares of our common stock we issued and to use our best efforts to cause the Securities and Exchange Commission to declare the registration statement effective." http://investors.amedica.com/all-sec-filings/content/0000912282-16-000919/amedica424b3_121216.htm?TB_iframe=true&height=auto&width=auto&preload=false (You guys see the timing...preparation started 3Q or 4Q last year.)
Puzzle piece #5 Global Eagle Entertainment, Inc. filed Form NT for late 10K (on 3.16.2017), but updated investors about the waiver they asked from their lender on on 5.4.2017 (Failed to deliver Financial Statements on time) https://seekingalpha.com/filing/3535091 --- Amedica NEVER update investors about the waiver to Hercules & Hercules doesn't even "bitch" about Amedica's non timely to deliver Financial Statements which required per the Loan Agreement.
***Here I have another example of a company filed Form NT 10-Q on 5.11.2017: https://seekingalpha.com/filing/3546476 ...It only took 20 calendar days, they already filed Form 8-K to update their investors about the waiver to their lender due to non timely provide Financial Statements: https://seekingalpha.com/filing/3578346
Puzzle piece #6 Funds were loading in Q1 & possibly have been loading in Q2 as well https://fintel.io/so/us/amda
Puzzle piece #7 In collaboration with its auditors, Amedica continues to consider any potential impairment in relation to certain of its long-lived assets - "long-lived assets" language in 8K on 5.26.2017 http://investors.amedica.com/all-sec-filings/content/0001493152-17-005915/0001493152-17-005915.pdf & recent 8K again on 6.9.2017 http://investors.amedica.com/all-sec-filings/content/0001493152-17-006356/ex99-1.htm?
Other companies that have LATE SEC filings on 10K or 10Q, they DON'T use the same language or phrase of "long-lived asset" auditing in their 8-K.
JRJR:
On 11.15.2016, they filed Form NT 10-Q (non timely to file 10Q)
http://www.jrjrnetworks.com/profiles/investor/secDL.asp?b=2203&c=1403085&ID=000162828016021501/0001628280-16-021501
On 11.29.2016, they filed the 8-K (like the ones amda filed) explaining the reasons why it was late. In the filing below, can't find the phrase "long-lived asset" auditing like we saw in amda's 8K:
http://www.jrjrnetworks.com/profiles/investor/secDL.asp?b=2203&c=1403085&ID=000162828016021711/0001628280-16-021711
On 3.31.2017, they filed Form NT 10-K (non timely to file 10K)
http://www.jrjrnetworks.com/profiles/investor/secDL.asp?b=2203&c=1403085&ID=000162828017003248/0001628280-17-003248
On 4.20.2017, they filed the 8-K (like the ones amda filed) explaining the reasons why it was late. I can't find the phrase "long-lived asset" audting as well! Here is the 8K they filed:
http://www.jrjrnetworks.com/profiles/investor/secDL.asp?b=2203&c=1403085&ID=000162828017003963/0001628280-17-003963
IMNP:
On 3.31.2017, they filed Form NT 10-K
https://www.sec.gov/Archives/edgar/data/1208261/000114420417018152/v463220_nt10k.htm
On 5.16.2017, they filed Form NT 10-Q
https://www.sec.gov/Archives/edgar/data/1208261/000114420417027921/v467193_nt10q.htm
On 5.26.2017, they filed Form 8K (exactly like amda's 8K to explain the non timely to file Financial Statements, but guess what...there is no such phrase about auditing "long-lived asset" language in their 8K.
http://archive.fast-edgar.com//20170526/AIAT222CZM22KTZZ2R2R2ZZH37QSZB22Z292/
JMBA:
On 3.20.2017, they filed form NT 10-K for non timely to file their 10K:
http://ir.jambajuice.com/phoenix.zhtml?c=192409&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTExNDgwMDY5JkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3
On 3.24.2017, they filed form 8-K to explain why it was late, the language inside the 8K has no such phrase "long lived-assets" like amda's 8K:
http://ir.jambajuice.com/phoenix.zhtml?c=192409&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTExNDg5ODg2JkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3
On 5.15.2017, they filed from NT 10-Q for non timely to file their 10Q:
http://ir.jambajuice.com/phoenix.zhtml?c=192409&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTExNTk5MTgwJkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3
On 5.19.2017, they file form 8-K to explain why it was late, the language inside the 8K has no such phrase "long lived-assets" like amda's 8K:
http://ir.jambajuice.com/phoenix.zhtml?c=192409&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTExNjA5NDc0JkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3
As you can see, this is 3rd example so far that proves amda's 8K really hinting the on-going audits in process is related to acquisition!
There are 2 major scenarios that they will audit long-lived assets:
#1 BK <<<<< Does amda looks like they will fold (Chapter 11)? HECK NO! This happened a lot back in 2008 crash, downturn of the market...when Compound annual growth rate (CAGR) of most companies in the negative.
#2 ACQUISITION <<<<< Measuring the fair value before sale/purchase of assets.
Am I the only ones that have this thinking of "BO" based on the language used of "long-lived assets" in their 8K? Think NOT! Coincidentally, the author in this article below has the same thought:
"When companies file these 8Ks, it’s unusual to reference long-lived assets in particular as the driving factor, and that Amedica was dressing itself up for acquisition would explain this specific reference."
https://www.insiderfinancial.com/amedica-corporation-nasdaqamda-looks-set-for-revaluation/123437/
Below is the links to 3 different reference reading material regarding "long-lived assets" auditing:
https://www2.deloitte.com/content/dam/Deloitte/us/Documents/audit/ASC/Roadmaps/us-aers-roadmap-to-reporting-discontinued-operations.pdf (For the target company)
https://media2.mofo.com/documents/1506practicepointersonfinancialstatement.pdf (For both target & acquirer companies to produce GAAP)
http://www.cheneliere.info/cfiles/complementaire/complementaire_gm/fichiers/certif/8410_fvtoolkit.pdf (Measuring fair value of a company before sale/purchase took place)
An example of 3-year book auditing before an acquisition took place:
http://www.timesunion.com/allwcm/article/Albany-Molecular-bought-by-private-firms-for-922M-11199035.php
This is their 10K/A shows they went back & audited 3 yrs for Deferred tax asset (is considered an intangible type of long-lived asset group):
http://ir.amriglobal.com/secfiling.cfm?filingID=1144204-17-25746&CIK=1065087
As you can see, in the process of being acquired...they have to go back 3 years to audit the book completely (long-lived assets, tangible, intangible like intellectual properties, deferred tax asset, aka NOLs, etc...all belong to "asset group")
Here is an example of business combinations SEC filing, pay attention to the language they used:
https://www.sec.gov/Archives/edgar/data/1123845/000112384501500005/fifth1-ksb.htm
Puzzle piece #8 "All debt will retire by January 2018, or sooner. Absent new financing, Amedica expects to be compliant with its debt covenants under the Hercules loan through July 2017." First time ever they made this type of statement about paying their debt off early! http://investors.amedica.com/all-sec-filings/content/0001493152-17-006356/ex99-1.htm (Hercules loan PREVENTS take over! As of current, they have enough cash to pay off Hercules loan instantly!)
Puzzle piece #9 Insider Holdings isn't much, but shareholders voted to increase managements option pool. Why else would management ask for 800k increase (3 fold increase)?
https://imgur.com/OxQiLeS
https://www.sec.gov/Archives/edgar/data/1269026/000149315216010411/form8-k.htm
Below is an example that showed Intermec had the same events before they were acquired by Honeywell. First thing that similar is a proxy vote scheduled for May 22, 2012 & filed April 12, 2012. The proxy contains 2 major similarities with AMDA, the election of a new Auditing firm & a significant increase to the option pool for management (original amount was 1.5 million proxy increased it to 4.5 millions or 3.7 million issuable shares):
https://imgur.com/isqVbll And
https://www.sec.gov/Archives/edgar/data/1044590/000119312512159726/d317545ddef14a.htm
The scenarios are not exactly the same as Intermec filed its 10-Q 2 days later but consider that Intermec had over 2000 employees at the time while Amedica has 30...only 3 people in accounting.
The last link is the announcement of Intermec being Acquired by Honeywell 8 months after filing of the proxy:
https://imgur.com/voCw2UU (look at the "long-lived assets" language they used) And https://www.sec.gov/Archives/edgar/data/1044590/000119312512231672/d319657dnt10q.htm
Intermec Acquired by Honeywell news: http://www.businesswire.com/news/home/20121210005706/en/Intermec-Acquired-Honeywell-600-Million
Every acquisition timing is different. A Trading Halt & BO news could come anytime & give everyone a surprise! IMO!
================================================================================================================================================
I am a big believer in AMDA's CSC & Sonny's vision for the holly grail of spinal surgery:
Our 24-month CASCADE study was a blinded, randomized clinical trial that compared outcomes of cervical fusion between our composite silicon nitride devices manufactured with an integrated core of cancellous structured ceramic (CsC), to the existing standard, i.e., PEEK (polyether ether ketone plastic) spacers filled with bone autograft.
The CASCADE study enrolled patients in a prospective trial that independently scored fusion rates and clinical outcomes at 24 months. The study was designed to compare the effects of our porous silicon nitride versus bone autograft - the patient's own bone - on patient outcomes. The silicon nitride interbody device was wetted with blood from the surgery site, but had no extrinsic bone graft material added to it. The control group was a PEEK, plastic, cage filled with bone autograft harvested during the decompressive discectomy. Results showed comparable clinical and radiographic performance between porous silicon nitride and bone autograft through a number of validated scientific clinical outcome measures.
"Porous silicon nitride is the first synthetic material to demonstrate spinal fusion outcomes that are similar to the patient's own bone," said Dr. Sonny Bal, chairman and CEO of Amedica Corporation.
This is the result of the CASCADE (24 months blind studies):
https://link.springer.com/article/10.1007%2Fs00586-017-5079-6
Even the SNAP Trial shows excellent result: "Results from Amedica’s CASCADE clinical trial showing effective spine fusion with porous silicon nitride without added bone graft are now published in the European Spine Journal. A similar trial (SNAP) compared silicon nitride to PEEK in lumbar fusion; preliminary data from the SNAP trial are consistent with previous observations that silicon nitride shows enhanced and earlier spine fusion than PEEK." Said Sonny in the filing:
https://www.sec.gov/Archives/edgar/data/1269026/000149315217006356/ex99-1.htm
The study of Valeo OL Interbody Fusion Devices for Posterior Lumbar Interbody Fusion SNAP Trial (SNAP):
https://clinicaltrials.gov/ct2/show/results/NCT01557829
Traditional way of Spine Fusion Surgery:
https://www.spine-health.com/treatment/spinal-fusion/autograft-patients-own-bone
https://www.spine-health.com/video/spine-fusion-surgery-video
CSC procedure will eliminate the need of the step in the video at 1:05 to 1:15: NO NEED TO CUT THE 2ND SITE ON PATIENTS TO GRAFT BONE!
This less invasive spinal fusion surgery procedure can ONLY be done with AMDA's unique Si3N4 Biomaterial! Check this presentation out (page 8):
http://c.eqcdn.com/_5c7526ae538a6086a4025ef13f5136d2/amedica/db/224/1039/pdf/AMDA_Investor+Presentation_Jan++2017.pdf
The above presentation, check page 15 for the comparison between 1st & 2nd Generation! Significantly Improve! Osteoconductivity increased 190% over current silicon nitride composition.
The recently obtained 2nd generation Si3N4 Worldwide Patent in many countries:
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017027426 (This is the priceless piece of long-lived asset!!!)
IMO, CSC will be all handled by Zimmer post acquisition. So the bashing about CSC by bears is moot point as of now.
IMO, Valeo® C+CsC using 2nd Generation Si3N4 is the future, the holly grail of spinal surgery:
CSC method will be a game changer forever! Less complicated procedures for surgeons & less risk of getting lawsuits for hospitals. Cheaper for insurance company. Greatly reduce the pain for patients (no need to harvest bone from 2nd site) & faster healing time. Most important is reducing the needs to inject invasive anti-infective drugs post surgeries (esp. peek biomaterial = very high infection rate post surgery). THIS IS A BIG THREAT TO "PEEK" BIOMATERIAL, WHICH CONTROLLING THE SPINAL SURGERY MARKET! CSC is currently approved in Europe, but lack of sale due to the corrupted industries & dirty plays by market controller "PEEK" biomaterial. Once AMDA' Si3n4 in the hand of Zimmer Biomet (vast resources in sale channels), the playing field will be balanced!
IMO, This is the theory of low pps... DO NOT SHAKE THE BUSH & ALARM THE SNAKES (smart investors out there)...dressing amda pps like a real POS...so they can accumulate more shares @ cheaper price while they bash the hell out of AMDA using many techniques:
http://boards.fool.com/paid-stock-bashers-lp-13645949.aspx
When reading conversation between posters, I always think "mole planting" like the movie "The Departed"! The smart, advance level bashers will try to create FUD (Fear, Uncertainty, Doubts) for investors that are trying to read & do their DDs!
As for comparison with TBRA acquisition scenario to AMDA's low revenue:
1. TBRA had $1 million revenue but was bought out @ $1.7 BILLIONS plus they had a FAILED drug before the BO took place.
2. You see they have an internal audit of 10Q/A before the 8K of BO news too...very similar to what is happening to amda scenario
3. The buyer saw the value of TBRA failed drug...amda' Si3n4 2nd gen is priceless worldwide patents. In addition, Weigao deals alone is in the range of $300 mils..I don't really know how much amda valuation though.
Reference links of TBRA:
Date announced BO:
http://www.investors.com/news/tobira-shares-multiply-on-1-7-billion-buyout-from-allergan/
8k announced BO:
https://seekingalpha.com/filing/3229715
10Q shows only $1 mil revenue:
https://seekingalpha.com/filing/3179433
All SEC filings before their BO news:
https://seekingalpha.com/symbol/TBRA/key-data/filings
General Info about the $200+ Mils NOLs from amda & how much it worths in case of BO:
http://www.pepperlaw.com/resource/2483/21d3
In conclusion, only god knows the real valuation of AMDA!
================================================================================================================================================
Pre-acquisition Due Diligence for the acquirer:
https://www.forbes.com/sites/allbusiness/2014/12/19/20-key-due-diligence-activities-in-a-merger-and-acquisition-transaction/#55117fb74bfc
Will there be a strategic fit between the AMDA and the buyer (Zimmer Biomet - Based on speculation)?
Zimmer just filed form SD to disclose the biomaterial they used in the yr. of 2016:
http://archive.fast-edgar.com//20170531/A322S22DZZ2RN2ZZ2HZM2MXOJRBFEZ22Z29G/
"Products that we manufacture incorporating our Trabecular MetalTM Technology contain tantalum, a necessary conflict mineral."
Tantalum is toxic & considered pretty heavy:
http://metals.comparenature.com/en/titanium-vs-tantalum/comparison-11-57-0
Further dug in & found Zimmer acquired Implex Corp to obtain Trabecular Metal Technology:
http://investor.zimmerbiomet.com/news-and-events/news/archive/24-11-2003-192536938
At first, they thought the Trabecular Metal Technology is Holly Grail of Biomaterial (Bone Void Filling):
The myths of trabecular metal: 'the next best thing to bone':
http://www.eoj.eg.net/article.asp?issn=1110-1148;year=2013;volume=48;issue=4;spage=327;epage=329;aulast=Eid
Trabecular Metal image:
https://imgur.com/6rMvYev
AMDA'Si3N4 image:
https://imgur.com/wNUcdZJ
Si3N4 has biocompatible properties:
www.ijmse.net/uploadfile/2016/0715/20160715041827481.pdf
Look alike isn't it?
IMO, Zimmer Biomet buys Si3N4 tech. to replace their current inferior biomaterial Trabecular Metal with tons of recalls from FDA is like replacing 20 years old cheap brand car with a fully loaded, luxury, full of safety features new car!
Many billions of dollars from funds pulled in ZBH lately:
https://fintel.io/so/us/zbh
Blackrock bought almost $2 BILLIONS.
FMR LLC increased position from 0 share to 5,322,721 shares!
I don't think Weigao will handle the manufacturing process though. I would say it's more into the distributing & selling roles.
Weigao connects with AMDA.
If Zimmer buys AMDA & owns the contract from Weigao. Who will be the ones manufactures the products to distribute to Weigao?
Are they waiting for the last day to fix the issues of the manufacturing facilities in China? Or they are fixing them now & preparing for something later?
I have said already, AMDA is the bridge between Zimmer & Weigao to compete with Metronics & Strykers in China:
https://ryortho.com/breaking/medtronicrsquos-816-million-bet-on-china-kanghui/
Do you think this has something to do with the preparation for the Weigao deal?
http://global.kyocera.com/news/2016/0601_kgsg.html
This is not about making a tray of cookies and sell to kids...Implant products in human body. Many regulations clearance & preparations must be taken care beforehand.
ZBH's today 8-K...OMG OMG OMG!!!! YOU GUYS TELL ME WHAT IS THIS FOR??? lmao....preparation to manufacture 220K+ units for giant Weigao after they acquire amda? IMO..i think it is!
"Zimmer Biomet Holdings, Inc. issued a press release on June 13, 2017 announcing the resolution of the FDA Warning Letter related to its Zhejiang, China manufacturing facility. A copy of the press release is attached hereto as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report."
http://archive.fast-edgar.com//20170613/AI2V4Q2EZ22R4ZZ2222S2ZXMVU4JZZ22D292/
10 hours drive to Giant Weigao location:
https://www.google.com/maps/dir/Zhejiang,+China/Shandong,+China/@32.4318906,114.9389359,6z/data=!3m1!4b1!4m14!4m13!1m5!1m1!1s0x34491234a50accbf:0x81ef71c536187cb7!2m2!1d119.7889248!2d29.1416432!1m5!1m1!1s0x358fcd4735ab4f7f:0xd93a2e2370e1b364!2m2!1d117.9249002!2d35.8939566!3e0
China Giant Weigao 220K+ units pending CFDA:
http://imgur.com/a/O7JgL
Looks like another connection & piece of puzzle just shows up today.
Like I have said before, AMDA is their bridge to China market due to the deal signed with giant Weigao pending CFDA. Zimmer & Strykers are fighting hard to gain market share in ASIA. tamand on ST is bashing for Stry***
Boston, some fool on ST says Zimmer invested in Peek & won't spend $ to buy amda....looky...looky:
https://www.aboutlawsuits.com/zimmer-peek-ardis-inserter-recall-38959/
Patient: ChristopherOctober 31, 2015 at 7:02 pm Reply
Received fusion (L5-S1) Oct 27, 2009. Had a break Oct 29, 2009. They PEEK cage was ‘repaired’ Nov 2, 2009.
I have operative report and film.
Not sure what broke or ‘anchor fastener’ broke or came loose 10/29/09.
- See more at: https://www.aboutlawsuits.com/zimmer-peek-ardis-inserter-recall-38959/#sthash.nY5lxZGT.dpuf
I am here man..was busy...I am almost done compiling all the DDs in one post...will post it later. There was a 200K bid today. Happy flippers shares were taken by thieves again today.
So you own 100K shares? And you want this to get delisted and trade on PINK sheet? LMAO...SMH...wink
Wink...said what? this will drop to .02 or .05? SMH...wink